2cureX AB
2cureX AB (publ) operates as a medical technology company in Europe. The company's principal product is IndiTreat, an IVD test for the treatment of cancer by establishing 3D copies of the patient's tumor and directly testing them against therapies. 2cureX AB (publ) was incorporated in 2006 and is based in Copenhagen, Denmark.
2cureX AB (2CUREX) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: 3.288x
Based on the latest financial reports, 2cureX AB (2CUREX) has a cash flow conversion efficiency ratio of 3.288x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr2.06 Million) by net assets (Skr626.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
2cureX AB - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how 2cureX AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
2cureX AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of 2cureX AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Asuransi Bintang Tbk
JK:ASBI
|
0.025x |
|
Martela Oyj A
HE:MARAS
|
0.082x |
|
BOD Science Ltd
AU:BOD
|
-0.175x |
|
Getaround Inc
OTCQB:GETR
|
0.607x |
|
ELAD SOFTWARE
TA:ELAD
|
-0.023x |
|
SWISS RE N
MU:SR9
|
N/A |
|
CINCINNATI FINANCL - Dusseldorf Stock Exchang
DU:CCJ
|
0.066x |
|
LKL International Bhd
KLSE:0182
|
0.144x |
Annual Cash Flow Conversion Efficiency for 2cureX AB (2015–2024)
The table below shows the annual cash flow conversion efficiency of 2cureX AB from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr5.10 Million | Skr-4.63 Million | -0.907x | +64.90% |
| 2023-12-31 | Skr12.08 Million | Skr-31.22 Million | -2.585x | -297.53% |
| 2022-12-31 | Skr43.03 Million | Skr-27.98 Million | -0.650x | -162.37% |
| 2021-12-31 | Skr74.34 Million | Skr-18.43 Million | -0.248x | -24.76% |
| 2020-12-31 | Skr58.86 Million | Skr-11.69 Million | -0.199x | +29.07% |
| 2019-12-31 | Skr28.08 Million | Skr-7.86 Million | -0.280x | -431.76% |
| 2018-12-31 | Skr13.62 Million | Skr1.15 Million | 0.084x | +139.30% |
| 2017-12-31 | Skr20.24 Million | Skr-4.35 Million | -0.215x | -240.95% |
| 2016-12-31 | Skr7.91 Million | Skr1.21 Million | 0.152x | +160.87% |
| 2015-12-31 | Skr8.19 Million | Skr-2.05 Million | -0.250x | -- |